Companion Diagnostics Market Size, Share, and Growth Analysis, By Product & Service (Assays, Kits, and Reagents, Instruments & Systems, Software & Services), By Technology (PCR, ISH, NGS, IHC), By Indication (Cancer, Neurological Diseases, Cardiovascular Diseases), By Sample Type (Tissue, Blood, Bone Marrow Samples), By End User (Academic and Research, Pharmaceutical & Biotechnology Companies), By Region, and Segment Forecast, 2026-2033

Report ID: SQMIG35J2130 | Region: Global | Published Date: May, 2025
Pages: 191 |Tables: 160 |Figures: 78

To request a free sample copy of this report, please complete the form below.

Our Clients

Schineder Electric

KSIA - Korea Semiconductor Industry Association

Hitachi Astemo Limited

Samsung Electronics

Halvo holdings

NTT corporation

AGC Inc

Siemens AG

Unilever

Merck Pharmaceuticals

Atlas Copco

Hologic - Medical Technology company

Novartis

Henkel

Reckitt

Schineder Electric

KSIA - Korea Semiconductor Industry Association

Hitachi Astemo Limited

Samsung Electronics

Halvo holdings

NTT corporation

AGC Inc

Siemens AG

Unilever

Merck Pharmaceuticals

Atlas Copco

Hologic - Medical Technology company

Novartis

Henkel

Reckitt

FAQs

Global Companion Diagnostics market size was valued at USD 8.72 Billion in 2024 and is poised to grow from USD 9.75 Billion in 2025 to USD 23.8 Billion by 2033, growing at a CAGR of 11.8% in the forecast period (2026–2033).

F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (United States), QIAGEN (Netherlands), Thermo Fisher Scientific Inc. (United States), Abbott Laboratories (United States), Danaher Corporation (United States), Guardant Health, Inc. (United States), Illumina, Inc. (United States), bioMérieux (France), ICON plc (Ireland), Myriad Genetics, Inc. (United States), Sysmex Corporation (Japan), The McClay Foundation (Almac Group) (United Kingdom), ARUP Laboratories (United States), Abnova Corporation (Taiwan), BioGenex (United States), Invivoscribe, Inc. (United States), Laboratory Corporation oof America (ArcherDX, Inc.) (United States), Amoy Diagnostics Co., Ltd. (China), Bio-Techne (Asuragen, Inc.) (United States)

The key driver of the companion diagnostics market is the increasing demand for personalized medicine, which relies on diagnostic tests to identify patients likely to benefit from specific therapies, improving treatment efficacy, safety, and overall patient outcomes.

A key market trend in the companion diagnostics market is the growing integration of molecular diagnostics and biomarker-based testing, enabling more precise patient stratification, targeted therapies, and the development of personalized treatment plans in oncology and other therapeutic areas.

North America accounted for the largest share in the companion diagnostics market, driven by advanced healthcare infrastructure, strong adoption of precision medicine, significant R&D investments, and the presence of leading diagnostic and pharmaceutical companies.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Luca Giovannini, Marketing Innovation Senior Manager, Trelleborg.

To request a free sample copy of this report, please complete the form below.

Our Clients

FAQs

What is the global market size of Companion Diagnostics Market?

Who are the key vendors in the Companion Diagnostics Market?

What is the key driver of Companion Diagnostics Market?

What is the key market trend for Companion Diagnostics Market?

Which region accounted for the largest share in Companion Diagnostics Market?

$5,300